Raymond James & Associates’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-24,745
| Closed | -$250K | – | 3846 |
|
|
2022
Q4 | $250K | Sell |
24,745
-2,239
| -8% | -$22.6K | ﹤0.01% | 3301 |
|
|
2022
Q3 | $605K | Sell |
26,984
-2,831
| -9% | -$63.5K | ﹤0.01% | 2727 |
|
|
2022
Q2 | $739K | Buy |
29,815
+379
| +1% | +$9.39K | ﹤0.01% | 2642 |
|
|
2022
Q1 | $1.14M | Buy |
29,436
+8,790
| +43% | +$341K | ﹤0.01% | 2489 |
|
|
2021
Q4 | $1.21M | Buy |
20,646
+250
| +1% | +$14.6K | ﹤0.01% | 2492 |
|
|
2021
Q3 | $1.21M | Buy |
20,396
+355
| +2% | +$21K | ﹤0.01% | 2447 |
|
|
2021
Q2 | $1.74M | Buy |
20,041
+16
| +0.1% | +$1.39K | ﹤0.01% | 2190 |
|
|
2021
Q1 | $1.65M | Sell |
20,025
-2,934
| -13% | -$242K | ﹤0.01% | 2145 |
|
|
2020
Q4 | $2.09M | Buy |
22,959
+2,534
| +12% | +$230K | ﹤0.01% | 1864 |
|
|
2020
Q3 | $816K | Sell |
20,425
-925
| -4% | -$37K | ﹤0.01% | 2292 |
|
|
2020
Q2 | $733K | Sell |
21,350
-900
| -4% | -$30.9K | ﹤0.01% | 2337 |
|
|
2020
Q1 | $494K | Sell |
22,250
-11,997
| -35% | -$266K | ﹤0.01% | 2420 |
|
|
2019
Q4 | $670K | Sell |
34,247
-6,210
| -15% | -$121K | ﹤0.01% | 2514 |
|
|
2019
Q3 | $628K | Buy |
40,457
+5,819
| +17% | +$90.3K | ﹤0.01% | 2496 |
|
|
2019
Q2 | $703K | Buy |
34,638
+2,090
| +6% | +$42.4K | ﹤0.01% | 2423 |
|
|
2019
Q1 | $572K | Buy |
32,548
+5,110
| +19% | +$89.8K | ﹤0.01% | 2557 |
|
|
2018
Q4 | $352K | Sell |
27,438
-1,850
| -6% | -$23.7K | ﹤0.01% | 2767 |
|
|
2018
Q3 | $477K | Buy |
29,288
+2,085
| +8% | +$34K | ﹤0.01% | 2731 |
|
|
2018
Q2 | $308K | Buy |
27,203
+453
| +2% | +$5.13K | ﹤0.01% | 2992 |
|
|
2018
Q1 | $261K | Buy |
26,750
+3,725
| +16% | +$36.3K | ﹤0.01% | 2963 |
|
|
2017
Q4 | $141K | Buy |
+23,025
| New | +$141K | ﹤0.01% | 3119 |
|